Export 160 results:
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is J  [Clear All Filters]
2017
Borry, P., Bentzen, H. B., Budin-Ljøsne, I., Cornel, M. C., et al. (2017). The challenges of the expanded availability of genomic information: an agenda-setting paper. Journal of Community Genetics.
Domingues, N., Estronca, L. M. B. B., Silva, J., Encarnação, M. R., et al. (2017). Cholesteryl hemiesters alter lysosome structure and function and induce proinflammatory cytokine production in macrophages. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1862(2), 210 - 220.
Maia, N., Loureiro, J. R., Oliveira, B., Marques, I., et al. (2017). Contraction of fully expanded FMR1 alleles to the normal range: Predisposing haplotype or rare events?. Journal of Human Genetics, 62(2), 269 - 275.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Höhn, A., Weber, D., Jung, T., Ott, C., et al. (2017). Happily (n)ever after: Aging in the context of oxidative stress, proteostasis loss and cellular senescence. Redox Biology, 11, 482 - 501.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet, 390(10091), 231 - 266.
Cunha, C., Gonçalves, S. M., Duarte-Oliveira, C., Leite, L., et al. (2017). IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. Journal of Allergy and Clinical Immunology, 140(3), 867 - 870.e9.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | WHISTLEBLOWER CHANNEL | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 226 074 900 | email: info@i3s.up.pt | © copyright 2010 ibmc